No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
Effects of omega-3 supplementation on muscle mass growth: an umbrella review of systematic reviews of randomised controlled trials
Abstract
The article examines the effect of omega-3 supplements on muscle growth. The effect of omega-3 supplementation on muscle mass growth is a hot topic of interest to athletes, fitness enthusiasts and researchers. Although individual studies and reviews are available, there is a lack of synthesis and analysis of the results of multiple randomized controlled trials on this topic. This creates uncertainty regarding the efficacy of omega-3 for increasing muscle mass. Purpose. To conduct an umbrella review of systematic reviews of randomized controlled trials to assess the effects of omega-3 supplementation on muscle mass growth and to identify general conclusions and recommendations. Methods. A search for systematic reviews in major databases including PubMed, Cochrane Library and Epistemonikos was conducted using relevant keywords. Suitable reviews highlighting the effects of omega-3 on muscle growth were selected. Conclusion. Systematic reviews of critically low quality provide conflicting evidence. There is currently no evidence to recommend omega-3 as a supplement to stimulate muscle growth in athletes and physically active individuals.
ResearchGate has not been able to resolve any citations for this publication.
Sarcopenia negatively affects skeletal muscle mass and function in older adults. Omega-3 (ω-3) fatty acid supplementation, with or without resistance exercise training (RET), is suggested to play a role as a therapeutic component to prevent or treat the negative effects of sarcopenia. A systematic review and meta-analysis were conducted on the impact of ω-3 fatty acid supplementation with or without RET on measures of muscle mass and function in older adults (≥55 y). The data sources included SPORTDiscus, PubMed, and Medline. All the study types involving ω-3 fatty acid supplementation on measures of muscle mass and function in older adults (without disease) were included. The mean differences (MDs) or standardized mean differences (SMDs) with 95% confidence intervals were calculated and pooled effects assessed. Sixteen studies (1660 females, 778 males) met our inclusion criteria and were included in the meta-analysis. ω-3 fatty acid supplementation did not impact lean tissue mass (SMD 0.09 [−0.10, 0.28]). Benefits were observed for lower body strength (SMD 0.37 [0.16, 0.59]), timed-up-and-go (MD 0.29 [0.23, 0.35]s), and 30-s sit-to-stand performance (MD 1.93 [1.59, 2.26] repetitions) but not walking performance (SMD 0.05 [−0.04, 0.13]) or upper body strength (SMD 0.05 [−0.04, 0.13]). Supplementing with ω-3 fatty acids may improve the lower-body strength and functionality in older adults.
Background & aims
Sarcopenia is characterized by the progressive loss of skeletal muscle mass and function, which reduces mobility and quality of life. Risk factors for sarcopenia include advanced age, physical inactivity, obesity, and chronic diseases such as cancer or rheumatoid arthritis. Omega-3 long chain polyunsaturated fatty acids (LC PUFAs) might be associated with a reduction in risk of sarcopenia due to their anti-inflammatory effects.
Methods
We conducted a systematic review and meta-analysis to quantify the effects of omega-3 LC PUFAs on muscle mass, volume and function parameters. The National Library of Medicine's MEDLINE/PubMed database was searched on 9th October 2020 for randomized controlled trials that used omega-3 LC PUFAs as an intervention with muscle-related endpoints. A snowballing search to identify additional studies was completed on 23rd April 2021. The meta-analysis was conducted using meta-essentials worksheet 3. Bias was assessed using the Jadad scale.
Results
123 studies were identified with the systematic searches. Most studies were performed in disease populations, such as cancer or chronic obstructive pulmonary disease (COPD), or in healthy individuals after a fatiguing exercise bout. The endpoints lean body mass, skeletal muscle mass, mid-arm muscle circumference, handgrip strength, quadriceps maximal voluntary capacity (MVC), and 1-repetition maximum chest press were selected for meta-analysis based on the number of available studies; thus 66 studies were included in the quantitative synthesis. Using a random effects model and 2-tailed p-value, there was a significant relationship in favor of omega-3 LC PUFA supplementation for lean body mass (effect size 0.27, 95%CI 0.04 to 0.51), skeletal muscle mass (effect size 0.31, 95%CI 0.01 to 0.60) and quadriceps MVC (effect size 0.47, 95%CI 0.02 to 0.93).
Conclusion
The results indicate that there is a positive effect of omega-3 LC PUFA supplementation on overall body muscle mass and strength. Small study size and heterogeneity limit the applicability of these findings for sarcopenia prevention. Larger trials in populations at risk of sarcopenia would strengthen the evidence base.
Background & aims:
Results from narrative reviews showed potential from omega-3 supplementation on lean body mass. In older adults, a previous meta-analysis showed significant results from omega-3 on lean body mass. This review aimed to investigate randomized clinical trials that evaluated the effects of omega-3 supplementation, compared to placebo, on lean body mass in humans.
Methods:
A systematic review and meta-analysis were conducted in Pubmed, LILACS, SciELO, Web of Science, Scopus, Embase, SPORTDiscus, and Cochrane Library. The authors assessed the risk of bias using the Cochrane tool. Randomized clinical trials that evaluated the effects of omega-3 supplementation compared to placebo on lean body mass were included.
Results:
In total, 11 studies were included, from which two found significant effects on lean body mass. In the meta-analysis, none of the results were significant.
Conclusions:
Omega-3 supplementation had no significant effect on lean body mass compared to placebo.
Background
Omega-3 fatty acids (FAs) have been suggested as a beneficial supplement in chronic kidney disease (CKD) patients, but the results of randomized clinical trials (RCTs) are controversial. We conducted a systematic review and meta-analysis to evaluate all the RCTs about the impact of omega-3 FAs supplementation on cardiometabolic outcomes and oxidative stress parameters in patients with CKD.
Methods
We performed a systematic database search in PubMed/MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Central, up to May 2020. We included all placebo-controlled randomized trials that assessed the effect of omega-3 FAs supplementation on any cardiometabolic outcomes: blood pressure, total cholesterol (TC), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) or triglycerides (TG) and oxidative stress parameters. Data were pooled using DerSimonian–Laird’s random-effects model.
Results
Finally, thirteen articles met the inclusion criteria for this review omega-3 FAs supplementation significantly decrease TC (SMD: -0.26; 95% CI: − 0.51, − 0.02; I² = 52.7%), TG (SMD: -0.22; 95% CI: − 0.43, − 0.02; I² = 36.0%) and Malondialdehyde (MDA) levels (SMD: -0.91; 95% CI: − 1.29, − 0.54; I² = 00.0%) and also significantly increase superoxide dismutase (SOD) (SMD: 0.58; 95% CI: 0.27, 0.90; I² = 00.0%) and Glutathione peroxidase (GPx) (SMD: 0.50; 95% CI: 0.14, 0.86; I² = 00.0%) activities. However our results show that omega-3 FAs supplementation have no significant effects on HDL, LDL and blood pressure.
Conclusion
This systematic review and meta-analysis supports current evidence for the clinical benefit of omega-3 FAs intake to improve cardiometabolic parameters in CKD patients. However, well-designed RCTs still needed to provide a conclusive picture in this field.
There is increasing evidence showing the role of fatty acids and their derived lipid intermediates in the regulation of skeletal muscle mass synthesis and function. However, the role of omega-3 fatty acids remains unclear. Therefore, we conducted a meta-analysis to evaluate the potential effects of omega-3 fatty acids on sarcopenia-related performances among the elderly. Eligible literature and reports of randomized controlled trials were comprehensively searched from the PubMed, Cochrane Library, ClinicalTrials.gov, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases until July 2018. A total of 10 articles were available for the meta-analysis. There were minor benefits for muscle mass gain (0.33 kg; 95% CI: 0.05, 0.62) and timed up and go performance (−0.30 s; 95% CI: −0.43, −0.17). Subgroup analyses regarding muscle mass and walk speed indicated that omega-3 fatty acid supplements at more than 2 g/day may contribute to muscle mass gain (0.67 kg; 95% CI: 0.16, 1.18) and improve walking speed, especially for those receiving more than 6 months of intervention (1.78 m/sec; 95% CI: 1.38, 2.17). Our findings provide some insight into the effects of omega-3 fatty acids on muscle mass, especially for those taking supplements at more than 2 g/day. We also observed that a long period of omega-3 fatty acids supplementation may improve walking speed.
Despite almost 25 years of fish oil supplementation (FS) research in athletes and widespread use by the athletic community, no systematic reviews of FS in athletes have been conducted. The objectives of the systematic review are to: 1) provide a summary of the effect of FS on the athlete’s physiology, health and performance; 2) report on the quality of the evidence; 3) document any side effects as reported in the athlete research; 4) discuss any risks associated with FS use; 5) provide guidance for FS use and highlight gaps for future research. Electronic databases (PubMed, EMBASE, Web of Science, Google Scholar) were searched up until April 2019. Only randomised placebo-controlled trials (RCTs) in athletes, assessing the effect of FS on a health, physiological/biochemical, or performance variable were included. Of the 137 papers identified through searches, 32 met inclusion criteria for final analysis. Athletes varied in classification from recreational to elite, and from Olympic to professional sports. Mean age for participants was 24.9 4.5 years, with 70% of RCTs in males. We report consistent effects for FS on reaction time, mood, cardiovascular dynamics in cyclists, skeletal muscle recovery, the pro-inflammatory cytokine TNF-alpha, and post-exercise nitric oxide responses. No clear effects on endurance performance, lung function, muscle force or training adaptation were evident. Methodological quality, applying the PEDro scale, ranged from 6 to a maximum of 11, with only four RCTs reporting effect sizes. Few negative outcomes were reported. We report various effects for FS on the athlete’s physiology; the most consistent findings were on the central nervous system, cardiovascular system, pro-inflammatory cytokines, and skeletal muscle. We provide recommendations for future research and discuss the potential risks with FS use.
We conducted a systematic review and meta-analysis to assess the effects of increasing dietary omega-3, omega-6 and mixed polyunsaturated fatty acids (PUFA) on musculoskeletal health, functional status, sarcopenia and risk of fractures. We searched Medline, Embase, The Cochrane library, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) databases for Randomised Controlled Trials (RCTs) of adults evaluating the effects of higher versus lower oral omega-3, omega-6 or mixed PUFA for ≥ 6 months on musculoskeletal and functional outcomes. We included 28 RCTs (7288 participants, 31 comparisons), 23 reported effects of omega-3, one of omega-6 and four of mixed total PUFA. Participants and doses were heterogeneous. Six omega-3 trials were judged at low summary risk of bias. We found low-quality evidence that increasing omega-3 increased lumbar spine BMD by 2.6% (0.03 g/cm², 95% CI − 0.02 to 0.07, 463 participants). There was also the suggestion of an increase in femoral neck BMD (of 4.1%), but the evidence was of very low quality. There may be little or no effect of omega-3 on functional outcomes and bone mass; effects on other outcomes were unclear. Only one study reported on effects of omega-6 with very limited data. Increasing total PUFA had little or no effect on BMD or indices of fat-free (skeletal) muscle mass (low-quality evidence); no data were available on fractures, BMD or functional status and data on bone turnover markers were limited. Trials assessing effects of increasing omega-3, omega-6 and total PUFA on functional status, bone and skeletal muscle strength are limited with data lacking or of low quality. Whilst there is an indication that omega-3 may improve BMD, high-quality RCTs are needed to confirm this and effects on other musculoskeletal outcomes.
The influence of nutrition has the potential to substantially affect physical function and body metabolism. Particular attention has been focused on omega-3 polyunsaturated fatty acids (n-3 PUFAs), which can be found both in terrestrial features and in the marine world. They are responsible for numerous cellular functions, such as signaling, cell membrane fluidity, and structural maintenance. They also regulate the nervous system, blood pressure, hematic clotting, glucose tolerance, and inflammatory processes, which may be useful in all inflammatory conditions. Animal models and cell-based models show that n-3 PUFAs can influence skeletal muscle metabolism. Furthermore, recent human studies demonstrate that they can influence not only the exercise and the metabolic response of skeletal muscle, but also the functional response for a period of exercise training. In addition, their potential anti-inflammatory and antioxidant activity may provide health benefits and performance improvement especially in those who practice physical activity, due to their increased reactive oxygen production. This review highlights the importance of n-3 PUFAs in our diet, which focuses on their potential healthy effects in sport.
The number of published systematic reviews of studies of healthcare interventions has increased rapidly and these are used extensively for clinical and policy decisions. Systematic reviews are subject to a range of biases and increasingly include non-randomised studies of interventions. It is important that users can distinguish high quality reviews. Many instruments have been designed to evaluate different aspects of reviews, but there are few comprehensive critical appraisal instruments. AMSTAR was developed to evaluate systematic reviews of randomised trials. In this paper, we report on the updating of AMSTAR and its adaptation to enable more detailed assessment of systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. With moves to base more decisions on real world observational evidence we believe that AMSTAR 2 will assist decision makers in the identification of high quality systematic reviews, including those based on non-randomised studies of healthcare interventions.
Soccer players often experience eccentric exercise-induced muscle damage given the physical demands of soccer match-play. Since long chain n-3 polyunsaturated fatty acids (n-3PUFA) enhance muscle sensitivity to protein supplementation, dietary supplementation with a combination of fish oil-derived n-3PUFA, protein and carbohydrate may promote exercise recovery. This study examined the influence of adding n-3PUFA to a whey protein, leucine and carbohydrate containing beverage over a 6 week supplementation period on physiological markers of recovery measured over 3 days following eccentric exercise. Competitive soccer players were assigned to one of three conditions (2 × 200mL): FO (n=10) contained n-3PUFA (1100mg DHA/EPA - approx. 550mg DHA, 550mg EPA), whey protein (15g), leucine (1.8g) and carbohydrate (20g); PRO (n=10) contained whey protein (15g), leucine (1.8g) and carbohydrate (20g) and CHO (n=10) contained carbohydrate (24g). Eccentric exercise consisted of unilateral knee extension/flexion contractions on both legs separately. Maximal force production was impaired by 22% during the 72 hour recovery period following eccentric exercise (p<0.05). Muscle soreness, expressed as AUC during 72 hour recovery, was less in FO (1948±1091 mm×72 h) than PRO (4640±2654 mm×72h, p<0.05) and CHO (4495±1853 mm×72h p=0.10). Blood concentrations of creatine kinase, expressed as AUC, were ~60% lower in FO compared to CHO (p<0.05) and tended to be lower (~39%, p = 0.07) than PRO. No differences in muscle function, soccer performance or blood c-reactive protein concentrations were observed between groups. In conclusion, the addition of n-3PUFA to a beverage containing whey protein, leucine and carbohydrate ameliorates the increase in muscle soreness and blood concentrations of creatine kinase following eccentric exercise in competitive soccer players.
The effects of n-3PUFA supplementation on skeletal muscle are currently unclear. The purpose of this systematic review was to synthesize all available evidence regarding the influence of n-3PUFA supplementation on muscle mass, strength, and function in healthy young and older adults. Four databases were searched (Medline, Embase, CochraneCENTRAL and SportDiscus). Pre-defined eligibility criteria were determined according to PICOS. Only peer-reviewed studies were included. The Cochrane RoB2 Tool and the NutriGrade approach were used to access risk of bias and certainty in evidence. Effect sizes were calculated using pre-post scores and analyzed using a three-level, random-effects meta-analysis. When sufficient studies were available, sub-analyses were performed in the muscle mass, strength, and function outcomes according to participant´s age (<60 or ≥60 years), supplementation dosage (<2 or ≥2 g/day), and training intervention (“resistance training” vs. “none or other”). Fourteen individual studies were included, totaling 1443 participants (913 females; 520 males) and 52 outcomes measures. Studies had high overall risk of bias and consideration of all NutriGrade elements resulted in a certainty assessment of moderate meta-evidence for all outcomes. n-3PUFA supplementation had no significant effect on muscle mass (SMD=0.07 [95%CI: -0.02; 0.17], p=0.11) and muscle function (SMD=0.03 [95%CI: -0.09; 0.15], p=0.58), but it showed a very small albeit significant positive effect on muscle strength (SMD=0.12 [95%CI: 0.006; 0.24], p=0.04) in participants when compared to placebo. Subgroup analyses showed that age, supplementation dose or co-supplementation alongside resistance training did not influence these responses. In conclusion, our analyses indicated that n-3PUFA supplementation may lead to very small increases in muscle strength but did not impact muscle mass and function in healthy young and older adults. To our knowledge, this is the first review and meta-analysis investigating whether n-3PUFA supplementation can lead to increases in muscle strength, mass and function in healthy adults. Registered protocol: doi.org/10.17605/OSF.IO/2FWQT.
The use of omega-3 polyunsaturated fatty acids (n-3 PUFA) has been studied in physically active population, however, there is a lack of information about the effects of n-3 PUFA supplementation on people with a sedentary behavior or who are undergoing a period of limb immobilization. This systematic review aims to examine the effect of n-3 PUFA on lean mass and muscle protein synthesis (MPS) in absence of physical training. The PubMed, Web of Science, MEDLINE, CINAHL and SPORTDiscus databases were searched following the PRISMA guidelines. Only randomized controlled trials, at least single blind, performed with sedentary humans were considered. Seven studies on a total of 192 individuals were included. Five of the six studies which measured changes in skeletal muscle volume and mass showed higher values with n-3 PUFA. Only two studies measured skeletal muscle protein expression. Both showed beneficial effects of supplementation in muscle protein fractional synthesis rate (FSR), while no effect of n-3 PUFA was observed for mechanistic target of rapamycin (mTOR) and kinase protein (Akt). In addition, ribosomal protein S6 kinase 1 (p70s6k) improved with n-3 PUFA only in one study. Finally, the two studies which measured the skeletal muscle gene expression observed no effect of supplementation.
There is growing evidence that suggests that n-3 polyunsaturated fatty acids (PUFA) may improve physical performance when combined with proper training through modulation of muscle hypertrophy, muscle strength, and delayed onset muscle soreness (DOMS). This systematic review aims to examine the effect and optimal dosage of n-3 PUFA supplementation on muscle hypertrophy, muscle strength, and DOMS when combined with physical exercise. The PubMed, Web of Science, MEDLINE Complete, CINAHL and SPORTDiscus databases were searched following the PRISMA guidelines. Randomized controlled trials performed with healthy humans were considered. Fifteen studies with a total of 461 individuals were included in this systematic review. All of them measured muscle function (short physical performance test, range of motion (ROM), electromechanical delay (EMD), muscle echo intensity or muscle quality) and DOMS. Fourteen studies evaluated muscle strength and only six assessed muscle hypertrophy. Our results demonstrated that n-3 PUFA does not improve muscle hypertrophy, muscle strength or skeletal muscle biomarkers of inflammation and muscle damage beyond the benefits obtained by the training itself. Nevertheless, n-3 PUFA improves DOMS recovery and muscle function (measured by ROM, EMD and muscle quality).
The results of randomized controlled trials (RCTs) investigating supplemental n-3 polyunsaturated fatty acids (PUFA) on muscle mass and function have been inconsistent. The present study aimed to quantitatively evaluate the effect of n-3 PUFA supplementation on indicators of muscle mass and function in healthy subjects. A systematic literature search was conducted up to July 2020 with databases of PubMed and Web of science. The random-effects model was implemented to calculate the weighted mean difference of net change of indicators regarding muscle mass and function. A total of nine studies (thirteen treatment groups) with 2067 participants were included for data analysis. The summary estimate showed that n-3 PUFA supplementation significantly increased the grip strength (1.17 kg; 95% CI: 0.27, 2.08 kg). Non-significant effect was observed with respect to muscle mass parameters, including fat mass (-0.67 kg; 95% CI: -2.20, 0.87 kg) and lean mass (0.33 kg; 95% CI: -0.35, 1.00 kg). Regarding muscle function indicators, there were non-significant effects on walking speed (-0.01 m•s⁻¹; 95% CI: -0.03, 0.01 m•s⁻¹), time up and go test (-0.25 s; 95% CI: -0.55, 0.04 s), respectively. The findings of this study indicated that supplementation with n-3 PUFA might have beneficial effects to improve muscle mass and function in healthy participants. However, there was no significant improvement in the subjects' muscle mass. Whether n-3 PUFA supplementation has favorable effects in participants with sarcopenia are warranted to be further investigated.
Context:
Military personnel are subjected to physiologically stressful environments during combat and its associated training. Evidence suggests that fish oil-derived n-3 polyunsaturated fatty acids (FO n-3 PUFAs) may affect military personnel's performance by promoting or preserving lean body mass, strength, and power, while enhancing recovery from training-associated muscle damage.
Objective:
Following PRISMA guidelines, this systematic review assessed the evidence for FO n-3 PUFA supplementation across various military-relevant outcomes related to physical performance in healthy adult populations.
Data sources:
The PubMed, Embase, and the CINAHL databases were searched along with references lists of selected articles and reviews.
Data extraction:
Eighteen trials were assessed for bias, and descriptive data were extracted.
Data analysis:
Of the 18 studies included, 12 trials favored FO n-3 PUFA supplementation in ≥ 1 of the performance outcomes.
Conclusion:
Overall, FO n-3 PUFA supplementation likely preserves strength and very likely enhances recovery from physiological stress in young, healthy adults. However, FO n-3 PUFAs' role in promoting or preserving lean body mass or promoting strength is unclear and warrants additional investigation.
Systematic review registration:
PROSPERO registration no. CRD42020152786.
The health benefits of fish oil, and its omega-3 long chain polyunsaturated fatty acid content, have attracted much scientific attention in the last four decades. Fish oils that contain higher amounts of eicosapentaenoic acid (EPA; 20:5n-3) than docosahexaenoic acid (DHA; 22:6n-3), in a distinctive ratio of 18/12, are typically the most abundantly available and are commonly studied. Although the two fatty acids have traditionally been considered together, as though they were one entity, different physiological effects of EPA and DHA have recently been reported. New oils containing a higher quantity of DHA compared with EPA, such as fractionated and concentrated fish oil, tuna oil, calamari oil and microalgae oil, are increasingly becoming available on the market, and other oils, including those extracted from genetically modified oilseed crops, soon to come. This systematic review focuses on the effects of high DHA fish oils on various human health conditions, such as the heart and cardiovascular system, the brain and visual function, inflammation and immune function and growth/Body Mass Index. Although inconclusive results were reported in several instances, and inconsistent outcomes observed in others, current data provides substantiated evidence in support of DHA being a beneficial bioactive compound for heart, cardiovascular and brain function, with different, and at times complementary, effects compared with EPA. DHA has also been reported to be effective in slowing the rate of cognitive decline, while its possible effects on depression disorders are still unclear. Interestingly, gender- and age- specific divergent roles for DHA have also been reported. This review provides a comprehensive collection of evidence and a critical summary of the documented physiological effects of high DHA fish oils for human health.
Systematic reviews aide the analysis and dissemination of evidence, using rigorous and transparent methods to generate empirically attained answers to focused research questions. Identifying all evidence relevant to the research questions is an essential component, and challenge, of systematic reviews. Gray literature, or evidence not published in commercial publications, can make important contributions to a systematic review. Gray literature can include academic papers, including theses and dissertations, research and committee reports, government reports, conference papers, and ongoing research, among others. It may provide data not found within commercially published literature, providing an important forum for disseminating studies with null or negative results that might not otherwise be disseminated. Gray literature may thusly reduce publication bias, increase reviews’ comprehensiveness and timeliness, and foster a balanced picture of available evidence.
Gray literature's diverse formats and audiences can present a significant challenge in a systematic search for evidence. However, the benefits of including gray literature may far outweigh the cost in time and resource needed to search for it, and it is important for it to be included in a systematic review or review of evidence. A carefully thought out gray literature search strategy may be an invaluable component of a systematic review. This narrative review provides guidance about the benefits of including gray literature in a systematic review, and sources for searching through gray literature. An illustrative example of a search for evidence within gray literature sources is presented to highlight the potential contributions of such a search to a systematic review. Benefits and challenges of gray literature search methods are discussed, and recommendations made.
Obesity is a major public health issue and an important contributor to the global burden of chronic disease and disability. Studies indicate that fish and omega-3 polyunsaturated fatty acids (n3-PUFA) supplements may help prevent cardiovascular and metabolic diseases. However, the effect of fish oil on body composition is still uncertain, so we performed a systematic review of randomized controlled trials and the first meta-analysis on the association between fish or fish oil intake and body composition measures. We found evidence that participants taking fish or fish oil lost 0.59 kg more body weight than controls (95% confidence interval [CI]: −0.96 to −0.21). Treatment groups lost 0.24 kg m−2 (body mass index) more than controls (−0.40 to −0.08), and 0.49 % more body fat than controls (−0.97 to −0.01). Fish or fish oil reduced waist circumference by 0.81 cm (−1.34 to −0.28) compared with control. There was no difference for fat mass and lean body mass. Further research is needed to confirm or refute our findings and to reveal possible mechanisms by which n3-PUFAs might reduce weight.
Aim:
Aim of the study was to examine the relationship between whole body skeletal muscle mass (SMM) and powerlifting performance in elite powerlifters.
Methods:
Twenty elite male powerlifters, including 4 world champions, volunteered. Muscle thickness (MTH) and subcutaneous fat thickness (FTH) were measured by ultrasound at 9 sites on the anterior and posterior aspects of the body. FTH was used to estimate body fat and fat-free mass and SMM was estimated from ultrasound-derived prediction equations. Best lifting performance in the squat (SQ), bench press (BP), and dead lift (DL) was recorded from competition performance.
Results:
Significant strong correlations (P<0.01) were observed between absolute and relative (divided by height) SMM and performance of the SQ (r=0.93 and r=0.94, respectively), BP (r=0.88 and r=0.87), and DL (r=0.84 and r=0.85). Relative lifting performance to SMM for squat (SQ/SMM ratio) and bench press (BP/SMM ratio) were constant throughout a wide range of weight classes (56kg-145kg) and there were no significant correlation between the SMM and those performances (r=0.21 for SQ and r=0.12 for BP). However, the DL/SMM ratio was negatively correlated to DL performance (r=-0.47, P<0.05).
Conclusion:
SMM is a good predictor of powerlifting performance throughout all weight classes.
Amatör ve profesyonel futbolcuların beslenme bilgi düzeylerinin İncelenmesi // Uluslararası İnsan bilimleri derg. -2010
- K Göral
- Ö Saygın
- K Karacabey
Göral K., Saygın Ö., Karacabey K. Amatör ve profesyonel futbolcuların beslenme bilgi düzeylerinin İncelenmesi // Uluslararası
İnsan bilimleri derg. -2010. -№ 7. -P. 836-856.